XFOR•benzinga•
X4 Pharmaceuticals Had $102.8M In Cash, Cash Equivalents, Restricted Cash, And Marketable Securities As Of December 31, 2024. Pro-forma For €28.5M Received From Norgine In January 2025 And The Expected Financial Impact Of The Strategic Restructuring Annou
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 25, 2025 by benzinga